search
Back to results

Investigating Non-invasive Brain Stimulation to Enhance Fluency in People Who Stutter (INSTEP)

Primary Purpose

Stuttering, Developmental

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Metronome-timed speech
Active tDCS
Sham tDCS
Sponsored by
University of Oxford
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stuttering, Developmental focused on measuring stammering, speech motor disorder, electrical current stimulation, metronome-timed speech

Eligibility Criteria

18 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Participant is willing and able to give informed consent for participation in the study.
  • Diagnosed with developmental stuttering of mild-moderate or greater severity
  • Native speaker of English
  • Normal or corrected-to-normal vision
  • Normal hearing

Exclusion Criteria:

  • Speech, language or communication disorder other than developmental stuttering.
  • Contraindication to brain stimulation (tDCS or TMS)
  • Contraindication to MRI
  • History of drug abuse
  • History of a neurological or psychiatric illness
  • Any previous neurosurgical procedures
  • Taking prescription or over-the-counter medication that may affect brain function (for example, anti-depressants)
  • Family history of epilepsy (first degree relative)
  • Severe claustrophobia (as they may be unable to tolerate scanner)

Sites / Locations

  • Department of Experimental Psychology, University of Oxford

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Active TDCS and Fluency Intervention

Sham TDCS and Fluency Intervention

Arm Description

Participants will receive 1-milliamp (mA) tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes a day for five consecutive days. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.

Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes a day for five consecutive days. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.

Outcomes

Primary Outcome Measures

Change in Stuttering Severity Instrument (SSI-4) Score
The Stuttering Severity Instrument (SSI-4) is a standardised measure of stuttering severity comprised of 3 sub-scores (frequency, duration and physical concomitants) which are summed to give a total score. We will use change from baseline in total score (i.e. baseline subtracted) on the Stuttering Severity Instrument version 4 measured post intervention. The maximum total score of the SSI-4 is 56, which corresponds to the highest stuttering severity. Therefore, larger negative change scores represent better outcomes (larger reductions in stuttering severity).

Secondary Outcome Measures

Change in percentage of disfluent syllables produced during conversation
Change from baseline (i.e. baseline subtracted) in percentage of disfluent syllables produced during a two-minute conversation sample. Larger negative change scores represent better outcomes (larger reductions in frequency of disfluency).
Change in percentage of disfluent syllables produced during reading
Change from baseline (i.e. baseline subtracted) in percentage of disfluent syllables produced during a two-minute reading sample. Larger negative change scores represent better outcomes (larger reductions in frequency of disfluency).
Change in Overall Assessment of the Speaker's Experience of Stuttering (OASES) score
The Overall Assessment of the Speaker's Experience of Stuttering (OASES) is a standardised self-assessment to measure the effect of stuttering on a person's life, comprising of 4 sub-scores (general information about speech, your reactions to stuttering, communication in daily situations, quality of life). The total score (out of a possible 500) is divided by the number of items (out of a possible 100. Note that some items may not apply to all participants). This gives a total impact score between 1 and 5, with 5 representing the highest negative impact on person's life. We will use change from baseline in total score (i.e. baseline subtracted) on the OASES total impact score, measured post intervention, as an outcome. Larger negative change scores represent better outcomes (larger reductions in negative impact of stuttering ).

Full Information

First Posted
October 26, 2017
Last Updated
May 17, 2022
Sponsor
University of Oxford
search

1. Study Identification

Unique Protocol Identification Number
NCT03335722
Brief Title
Investigating Non-invasive Brain Stimulation to Enhance Fluency in People Who Stutter
Acronym
INSTEP
Official Title
Investigating Non-invasive Brain Stimulation to Enhance Fluency in People Who Stutter
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
November 15, 2017 (Actual)
Primary Completion Date
June 1, 2020 (Actual)
Study Completion Date
June 1, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Oxford

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to test whether the application of transcranial direct current stimulation (tDCS) concurrent with fluency training results in improvements in speech fluency in adults with developmental stuttering, measured up to three months after the intervention.
Detailed Description
Developmental stuttering affects 5% of children and persists to adulthood in about 1%. Changing the way speech is produced in adults who stutter is a particular challenge for speech and language therapy and there is a need for novel interventions. One such intervention involves the application of transcranial direct current stimulation (tDCS) alongside therapies aimed at improving speech fluency. tDCS influences brain activity by modulating neuronal plasticity through the application of weak electrical currents across the brain. Pairing tDCS with speech therapy has potential for producing larger or longer lasting effects and reducing time spent in therapy. The study will evaluate the potential of tDCS combined with speech fluency training to improve outcomes in people who stutter (PWS). PWS will have this training while receiving tDCS for five days (1 milliampere [mA] for 20 mins per day) in a double-blind randomized controlled trial. Outcomes will be measured in terms of changes to stuttering severity. An additional research questions is how changes in interactions between sensory and motor brain regions relate to changes in speech fluency in PWS. MRI will be used to measure brain structure and function and the vocal tract during speech production. Transcranial magnetic stimulation (TMS) will assess motor excitability before and after the training.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stuttering, Developmental
Keywords
stammering, speech motor disorder, electrical current stimulation, metronome-timed speech

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Double-blind, placebo-controlled (sham tDCS), randomised trial, with 20 participants with developmental stuttering recruited for each of the two arms of the trial.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
A researcher from another research group who is not involved in any aspect of the trial will perform the randomisation of participants into the sham and tDCS study arms using a minimisation procedure within "randPack" package in R (Carey and Gentleman, 2016). Allocation concealment will be achieved by assigning a unique 5-digit code per participant (containing no identifying information regarding trial arm). This will be emailed to the researcher. The code is used to deliver stimulation via study mode on the stimulator (http://www.neurocaregroup.com/dc_stimulator_plus.html). The participants and the researchers who will deliver the intervention, assess the outcomes, and analyse the data will be masked to trial arm.
Allocation
Randomized
Enrollment
43 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active TDCS and Fluency Intervention
Arm Type
Active Comparator
Arm Description
Participants will receive 1-milliamp (mA) tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes a day for five consecutive days. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
Arm Title
Sham TDCS and Fluency Intervention
Arm Type
Sham Comparator
Arm Description
Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes a day for five consecutive days. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
Intervention Type
Behavioral
Intervention Name(s)
Metronome-timed speech
Intervention Description
Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.
Intervention Type
Device
Intervention Name(s)
Active tDCS
Intervention Description
1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.
Intervention Type
Device
Intervention Name(s)
Sham tDCS
Intervention Description
Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.
Primary Outcome Measure Information:
Title
Change in Stuttering Severity Instrument (SSI-4) Score
Description
The Stuttering Severity Instrument (SSI-4) is a standardised measure of stuttering severity comprised of 3 sub-scores (frequency, duration and physical concomitants) which are summed to give a total score. We will use change from baseline in total score (i.e. baseline subtracted) on the Stuttering Severity Instrument version 4 measured post intervention. The maximum total score of the SSI-4 is 56, which corresponds to the highest stuttering severity. Therefore, larger negative change scores represent better outcomes (larger reductions in stuttering severity).
Time Frame
1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Secondary Outcome Measure Information:
Title
Change in percentage of disfluent syllables produced during conversation
Description
Change from baseline (i.e. baseline subtracted) in percentage of disfluent syllables produced during a two-minute conversation sample. Larger negative change scores represent better outcomes (larger reductions in frequency of disfluency).
Time Frame
1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Title
Change in percentage of disfluent syllables produced during reading
Description
Change from baseline (i.e. baseline subtracted) in percentage of disfluent syllables produced during a two-minute reading sample. Larger negative change scores represent better outcomes (larger reductions in frequency of disfluency).
Time Frame
1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Title
Change in Overall Assessment of the Speaker's Experience of Stuttering (OASES) score
Description
The Overall Assessment of the Speaker's Experience of Stuttering (OASES) is a standardised self-assessment to measure the effect of stuttering on a person's life, comprising of 4 sub-scores (general information about speech, your reactions to stuttering, communication in daily situations, quality of life). The total score (out of a possible 500) is divided by the number of items (out of a possible 100. Note that some items may not apply to all participants). This gives a total impact score between 1 and 5, with 5 representing the highest negative impact on person's life. We will use change from baseline in total score (i.e. baseline subtracted) on the OASES total impact score, measured post intervention, as an outcome. Larger negative change scores represent better outcomes (larger reductions in negative impact of stuttering ).
Time Frame
6 weeks and 12 weeks after the end of the 5-day intervention
Other Pre-specified Outcome Measures:
Title
Change in Premonitory Awareness in Stuttering Scale
Description
Change in total score on measure of anticipation of stuttering
Time Frame
1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Title
Change in Beck Anxiety Inventory
Description
Change in total score on the Beck Anxiety Inventory
Time Frame
1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Title
Change in Subjective rating of stuttering severity
Description
Change in self-rating on 9 point scale
Time Frame
1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Title
Change in Subjective rating of speech naturalness
Description
Change in self-rating on 9 point scale
Time Frame
1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Title
Change in Objective rating of stuttering severity
Description
Change in Researcher rating on 9 point scale
Time Frame
1 week, 6 weeks and 12 weeks after the end of the 5-day intervention
Title
Change in Objective rating of speech naturalness
Description
Change in Researcher rating on 9 point scale
Time Frame
1 week, 6 weeks and 12 weeks after the end of the 5-day intervention

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Participant is willing and able to give informed consent for participation in the study. Diagnosed with developmental stuttering of mild-moderate or greater severity Native speaker of English Normal or corrected-to-normal vision Normal hearing Exclusion Criteria: Speech, language or communication disorder other than developmental stuttering. Contraindication to brain stimulation (tDCS or TMS) Contraindication to MRI History of drug abuse History of a neurological or psychiatric illness Any previous neurosurgical procedures Taking prescription or over-the-counter medication that may affect brain function (for example, anti-depressants) Family history of epilepsy (first degree relative) Severe claustrophobia (as they may be unable to tolerate scanner)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kate E Watkins, PhD
Organizational Affiliation
University of Oxford
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Experimental Psychology, University of Oxford
City
Oxford
ZIP/Postal Code
OX2 6BW
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://insteptrial.wordpress.com
Description
INSTEP trial website
URL
https://www.psy.ox.ac.uk/research/speech-brain-research-group
Description
Speech and Brain Research Group website

Learn more about this trial

Investigating Non-invasive Brain Stimulation to Enhance Fluency in People Who Stutter

We'll reach out to this number within 24 hrs